The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,106.00
Bid: 12,118.00
Ask: 12,122.00
Change: 86.00 (0.72%)
Spread: 4.00 (0.033%)
Open: 12,062.00
High: 12,182.00
Low: 12,032.00
Prev. Close: 12,106.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-UK shares weaken, Tullow loses half its market cap

Mon, 09th Dec 2019 09:23

* FTSE 100, FTSE 250 down 0.1%

* Tesco outshines the main index

* Some domestic stocks gain on election optimism

* Tullow Oil plummets after co cancels dividend, CEO exits
(Adds company news items, updates share moves)

By Muvija M and Shashwat Awasthi

Dec 9 (Reuters) - London's exporter-heavy FTSE 100 inched
lower on Monday as oil majors and Asia-exposed financials fell
on China growth worries and as the pound strengthened, while a
72% slump in Tullow Oil single-handedly dragged down midcaps.

The blue-chip index was gave up 0.1%, with its
dollar earners including spirits company Diageo and
pharmaceutical giant AstraZeneca taking a hit from gains
in sterling ahead of UK general election later this week.

The FTSE 250 midcap index was also down by the same
level, with Tullow Oil recording its steepest one-day
fall since early 2004 after the oil and gas explorer scrapped
dividend and announced the exit of its CEO.

Monday's drop wiped off roughly half of Tullow's market cap,
or 1 billion pounds ($1.28 billion), as the stock tumbled to its
lowest in 15-1/2 years. Rival Premier Oil also fell 8%.

Other news-related moves saw Tesco top the bluechip
index with a 5% rise after the retailer started a review of its
operations in Thailand and Malaysia.

Helping limit losses on the midcap bourse was engineering
firm Senior Plc, which jumped 7% on news that it was
reviewing options for its aerostructures business. Marks &
Spencer added 3.5% after a double upgrade from Goldman
Sachs.

Elsewhere, China's exports in November shrank for the fourth
consecutive month, fanning worries over the impact of the
Sino-U.S. trade war on the world's second-largest economy and
overshadowing Friday's strong U.S. jobs data.

"The contrasting U.S. and Chinese data should swing the
trade negotiation pendulum back to neutral from the Chinese side
amongst the world's trade watchers," OANDA analyst Jeffrey
Halley said.

Investors were also trying to size up the chances of a new
round of U.S. tariffs on $156 billion worth of Chinese goods
from Dec. 15.

While signs of progress in the trade negotiations lifted the
FTSE 100 to its biggest one-day gain since July on Friday, the
bourse still marked its steepest weekly fall after contradictory
messages from U.S. President Donald Trump earlier on.

"More soothing noises on the negotiations emerged from
Washington D.C. on Friday, but one gets the sense that this
Sunday's next round of tariffs on China is no longer the line in
the sand it once was perceived to be," Halley said.

On Monday, some of Britain's more domestically-exposed firms
such as Lloyds and Barclays outperformed as
investors bet on the Boris Johnson-led Conservatives to win the
election this week and deliver Brexit.

"Three days to polling day and the polls are looking good
for Boris Johnson..., although the spectre of tactical voting
still lingers," Raymond James analyst Chris Bailey said.

($1 = 0.7794 pounds)

(Reporting by Muvija M and Shashwat Awasthi in Bengaluru with
additional reporting by Tanishaa Nadkar; Editing by Arun Koyyur
and Mark Heinrich)

More News
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more
21 May 2024 12:03

CORRECT: Stocks fall but pound up as IMF ups UK forecast

(Correcting London Stock Exchange index prices.)

Read more
21 May 2024 12:00

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.